Dark

Check out our Dark Pool Levels

ASLN
ASLAN Pharmaceuticals Limited
stock NASDAQ

Inactive

Jul 18, 2024

0.6000USD-14.273%(-0.0999)806,352

Pre-market

0.00USD-100.000%(-0.70)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 21, 2022

08:08AM EST The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective Benzinga

05:19AM EST ASLAN Pharmaceuticals Initiates Phase 2b Study Of ASLAN004 In Moderate-To-Severe Atopic Dermatitis Benzinga

Jan 20, 2022

04:05PM EST -- The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor -- This dose-ranging study is expected to enroll approximately 300 patients and will evaluate 4 dose regimens -- Topline results are expected in 1H 2023 GlobeNewswire Inc

Jan 19, 2022

07:40AM EST The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data Benzinga

Jan 18, 2022

08:06AM EST -Management to host the second webinar in ASLANs A4 series on Thursday, January 20, 2022, at 12:00pm ET GlobeNewswire Inc

Jan 16, 2022

04:38PM EST The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week Benzinga

Jan 11, 2022

07:00AM EST - Data from Phase 1b dose escalation cohorts to be presented during the 2022 Winter Clinical Dermatology Conference, held in-person from 14-19 January, 2022, in Koloa, Hawaii GlobeNewswire Inc

Jan 6, 2022

07:00AM EST ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect GlobeNewswire Inc

Dec 6, 2021

07:10AM EST ASLAN Pharma Announces IQVIA Biotech as its Preferred Clinical Research Organization Benzinga

07:00AM EST ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic GlobeNewswire Inc

Nov 22, 2021

07:00AM EST ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will be participating in fireside chats at two upcoming virtual health conferences. The details are as follows: GlobeNewswire Inc

Nov 10, 2021

07:00AM EST ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th GlobeNewswire Inc

Oct 26, 2021

08:01AM EDT ASLAN Pharma Q3 Net Loss $8.6 Mln Vs Loss Of $3.5 Mln Last Year RTTNews

07:29AM EDT ASLAN Pharmaceuticals Q3 EPS $(0.02), Same YoY Benzinga

07:00AM EDT ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results GlobeNewswire Inc

Oct 22, 2021

07:08AM EDT ASLAN Pharma Reports Scientific Collab With Dr. Emma Guttman-Yassky On Identification Of Co.'s ASLAN004-Specific Biomarkers Benzinga

07:00AM EDT ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr GlobeNewswire Inc

Oct 18, 2021

07:00AM EDT -Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET GlobeNewswire Inc

Oct 14, 2021

07:00AM EDT ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory GlobeNewswire Inc

Sep 27, 2021

02:30PM EDT Mid-Afternoon Market Update: Dow Gains 150 Points; Red Cat Holdings Shares Spike Higher Benzinga

12:34PM EDT Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide Benzinga

10:15AM EDT Mid-Morning Market Update: Markets Mixed; US Durable Goods Orders Increase Sharply In August Benzinga

06:04AM EDT ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof Of Concept For ASLAN004 In Atopic Dermatitis Benzinga

06:00AM EDT -Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile GlobeNewswire Inc

Sep 22, 2021

07:00AM EDT ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual GlobeNewswire Inc

Sep 21, 2021

07:03AM EDT ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired By Distinguished Dermatology Expert Dr Lawrence Eichenfield Benzinga

07:00AM EDT ASLAN Pharmaceuticals Establishes Scientific Advisory Board GlobeNewswire Inc

Sep 9, 2021

07:00AM EDT ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual GlobeNewswire Inc

Sep 8, 2021

10:20AM EDT ASLAN Pharmaceuticals Option Alert: Oct 15 $5 Calls Sweep (22) near the Ask: 700 @ $0.45 vs 1227 OI; Ref=$3.03 Benzinga

Aug 6, 2021

07:05AM EDT ASLAN Pharmaceuticals Q2 EPS $(0.08) Up From $(0.10) YoY Benzinga

07:00AM EDT -- Recruitment completed in June for the expansion cohort of the Multiple Ascending Dose (MAD) trial of ASLAN004, underway for the treatment of patients with moderate-to-severe atopic dermatitis -- Topline, unblinded data from approximately 27 additional patients expected at the end of the third quarter of 2021 -- On track to initiate Phase 2b clinical trial for ASLAN004 in 4Q 2021 GlobeNewswire Inc

Aug 4, 2021

07:00AM EDT ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 09:00 am ET. The conference will be held from August 9 to August 10, 2021. GlobeNewswire Inc

Jul 13, 2021

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

08:03AM EDT ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development Benzinga

07:02AM EDT ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 GlobeNewswire Inc

Jul 9, 2021

08:32AM EDT Jefferies Initiates Coverage On ASLAN Pharmaceuticals with Buy Rating, Announces Price Target of $8 Benzinga

May 25, 2021

07:30AM EDT ASLAN Pharmaceuticals to Participate In Fireside Chat at Jefferies GlobeNewswire Inc

May 11, 2021

07:56AM EDT ASLAN Pharmaceuticals Q1 EPS $(0.02), Same YoY Benzinga

07:30AM EDT - Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021-Phase 2b clinical trial for ASLAN004 expected to initiate in the second half of 2021 GlobeNewswire Inc

May 5, 2021

05:23AM EDT - ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021 GlobeNewswire Inc

Apr 22, 2021

08:09AM EDT ASLAN Pharmaceuticals Q4 EPS $(0.15) Up From $(0.18) YoY Benzinga

07:51AM EDT ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its clinical development activities. GlobeNewswire Inc

Mar 18, 2021

07:27AM EDT ASLAN Pharmaceuticals Appoints Dr Kathleen Metters as Independent GlobeNewswire Inc

Mar 17, 2021

06:44AM EDT HC Wainwright & Co. Maintains Buy on ASLAN Pharmaceuticals, Raises Price Target to $8 Benzinga

Mar 3, 2021

12:43AM EST ASLAN Pharmaceuticals Announces Pricing of Public Offering of GlobeNewswire Inc

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

Mar 1, 2021

04:06PM EST ASLAN Pharmaceuticals Announces That It Proposed A Public Offering Of $60M ADS Benzinga

04:01PM EST ASLAN Pharmaceuticals Announces Proposed Public Offering of GlobeNewswire Inc

09:46AM EST Shares of ASLAN Pharmaceuticals Limited (ASLN) jumped over 30% on Monday morning after the company announced positive interim data from a study of skin disease treatment. RTTNews

09:31AM EST ASLAN Pharmaceuticals Shares Up 44%; Hearing PIPER Raises Price Target From $6 To Street-High $10 On Positive Data Benzinga

08:18AM EST Aslan Pharmaceuticals Shares Are Trading Higher On Positive ASLAN004 Data In Atopic Dermatitis Benzinga

06:11AM EST ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis Benzinga

06:00AM EST - 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 GlobeNewswire Inc

Feb 26, 2021

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

Feb 25, 2021

06:35AM EST ASLAN Pharmaceuticals Announces $18M Private Placement Benzinga

06:30AM EST ASLAN Pharmaceuticals Announces $18 Million Private Placement GlobeNewswire Inc

Feb 18, 2021

07:00AM EST ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director GlobeNewswire Inc

Feb 17, 2021

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 3, 2021

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 27, 2021

07:36AM EST The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement Benzinga

Jan 26, 2021

07:56AM EST ASLAN Pharmaceuticals Shares Up Premarket After Co. Highlights ASLAN003 Research Published in Toxicology in Vitro; Says Research Shows ASLAN003 'to have the lowest potential for hepatotoxicity of the compounds tested' Benzinga

07:30AM EST New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors GlobeNewswire Inc

Jan 11, 2021

05:34AM EST - ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels GlobeNewswire Inc

Nov 19, 2020

07:22AM EST ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler GlobeNewswire Inc

Nov 9, 2020

07:09AM EST ASLAN Pharmaceuticals Q3 EPS $(0.02) Up From $(0.03) YoY Benzinga

07:00AM EST ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2020 and provided an update on its clinical activities. GlobeNewswire Inc

Oct 22, 2020

07:38AM EDT Aslan Pharmaceuticals Initiates Third Dose Cohort Of ASLAN004 In Atopic Dermatitis Clinical Trial; ASLAN004 Found To Be Well Tolerated At 400mg Dose, Third Cohort Will Test 600mg Dose Benzinga

07:30AM EDT -- ASLAN has initiated recruitment of patients into thirddose cohort atsites in the US, Australia and Singapore following successful safety review of second cohort GlobeNewswire Inc

Oct 16, 2020

05:35AM EDT ASLAN Pharmaceuticals Announces Plans to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions Benzinga

05:25AM EDT -- ASLAN believes ASLAN003 has the potential to bethe most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide GlobeNewswire Inc

Sep 21, 2020

06:07AM EDT ASLAN Pharmaceuticals Completes Enrolment In Second Cohort And Opens New Sites In US And Australia In ASLAN004 Atopic Dermatitis Study Benzinga

06:01AM EDT ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and GlobeNewswire Inc

Aug 24, 2020

03:28AM EDT ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into GlobeNewswire Inc

Aug 7, 2020

03:00AM EDT ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG GlobeNewswire Inc

Aug 3, 2020

04:03AM EDT ASLAN Pharma Appoints Kenneth Kobayashi As Chief Medical Officer RTTNews

03:18AM EDT ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief GlobeNewswire Inc

Jul 17, 2020

06:11AM EDT ASLAN Pharma Reports Received Receipt Of Notice Of Delisting From Taipei Exchange In Further Progress Towards Primary Listing On Nasdaq Benzinga

06:09AM EDT ASLAN Pharmaceuticals Announces the Move of its Primary Listing to GlobeNewswire Inc

Jul 13, 2020

08:13AM EDT ASLAN Q2 Net Loss $4.0 Mln Vs Net Loss $7.9 Mln Last Year RTTNews

08:06AM EDT ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the second quarter ended 30 June 2020 and provided an update on its clinical activities. GlobeNewswire Inc

Share